GEN Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab
EN
07/10/2020

Underlying

GENGenmab A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genmab A/S

 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab Provides Certain Information Disclosed in Connection with Propo...

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab also launched the syndicatio...

November 10, 2025 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab Announces Proposed Private Offering of Senior Secured Notes and...

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab...

November 10, 2025 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab Announces Financial Results for the Nine Months of 2025

Genmab Announces Financial Results for the Nine Months of 2025 November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 millionFDA granted BTD to Rina-S® in advanced endometrial cancerEpcoritamab Phase 3 EPCORE® FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and clinically meaningful differences in both endpointsFDA granted priority review of th...

November 6, 2025 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab to Participate in a Fireside Chat at the Jefferies Global Healt...

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London Media ReleaseCOPENHAGEN, Denmark; November 5, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 12:00 PM GMT (7:00 AM EST) on November 19, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppa...

November 5, 2025 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 ...

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EP...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch